Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology

12-03-2025 | Aflibercept | Clinical Investigation

Comparison of intraocular pressure changes in Japanese patients with neovascular age-related macular degeneration treated with aflibercept or faricimab

Authors: Junichiro Honjo, Ryo Mukai, Kanako Itagaki, Keiichiro Tanaka, Koki Norikawa, Yutaka Kato, Akihito Kasai, Yukinori Sugano, Tetsuju Sekiryu

Published in: Japanese Journal of Ophthalmology

Login to get access

Abstract

Purpose

To assess the short-term changes in intraocular pressure (IOP) following intravitreal injections of aflibercept or faricimab in Japanese patients with neovascular age-related macular degeneration (nAMD).

Study Design

Retrospective observational study.

Methods

This retrospective observational study included 161 eyes from 160 Japanese patients diagnosed with nAMD. Of these, 127 eyes (127 patients) were treated with 2 mg/0.05 mL aflibercept, and 34 eyes (33 patients) received 6 mg/0.05 mL faricimab. Each group underwent three consecutive monthly injections. The IOP in each treated eye was measured using non-contact tonometry at each visit over a 3-month period following the initial injection.

Results

The mean baseline IOP in the aflibercept group was 14.4 ± 2.8 mmHg, decreasing to 13.2 ± 3.0 mmHg after 3 months (P < 0.001), whereas the mean baseline IOP in the faricimab group was 13.8 ± 2.1 mmHg, with a change to 13.5 ± 1.5 mmHg after 3 months (P = 0.1873).

Conclusion

The loading phase treatment with aflibercept resulted in a decrease in IOP. Faricimab showed a similar trend, there was no significant difference between the two treatments.
Literature
1.
Congdon N, O’Colmain B, Klaver CCW, Klein R, Muñoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–85.CrossRefPubMed
2.
Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153:209– 13.e2.
3.
Jonas JB, Cheung CMG, Panda-Jonas S. Updates on the epidemiology of age-related macular degeneration. Asia Pac J Ophthalmol (Phila). 2017;6:493–7.PubMed
4.
Barash A, Chui TYP, Garcia P, Rosen RB. Acute macular and peripapillary angiographic changes with intravitreal injections. Retina. 2020;40:648–56.CrossRefPubMed
5.
Pirinen I, Leinonen S, Helminen M, Hujanen P, Vaajanen A, Tuulonen A, et al. Glaucoma progression in patients receiving intravitreal anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol. 2023;101:261–5.CrossRefPubMed
6.
Baek SK, Kim JH, Kim JW, Kim CG. Increase in the population of patients with neovascular age-related macular degeneration who underwent long-term active treatment. Sci Rep. 2019;9:13264.CrossRefPubMedPubMedCentral
7.
Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye (Lond). 2021;35:1305–16.CrossRefPubMed
8.
Regula JT, von Lundh P, Foxton R, Barathi VA, Cheung CMG, Bo Tun SB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8:1265–88.CrossRefPubMedPubMedCentral
9.
Thomson BR, Heinen S, Jeansson M, Ghosh AK, Fatima A, Sung HK, et al. A lymphatic defect causes ocular hypertension and glaucoma in mice. J Clin Invest. 2014;124:4320–4.CrossRefPubMedPubMedCentral
10.
Thomson BR, Souma T, Tompson SW, Onay T, Kizhatil K, Siggs OM, et al. Angiopoietin-1 is required for Schlemm’s canal development in mice and humans. J Clin Invest. 2017;127:4421–36.CrossRefPubMedPubMedCentral
11.
Souma T, Tompson SW, Thomson BR, Siggs OM, Kizhatil K, Yamaguchi S, et al. Angiopoietin receptor TEK mutations underlie primary congenital glaucoma with variable expressivity. J Clin Invest. 2016;126:2575–87.CrossRefPubMedPubMedCentral
12.
Kim J, Park D-Y, Bae H, Park DY, Kim D, Lee C-K, et al. Impaired angiopoietin/Tie2 signaling compromises Schlemm’s canal integrity and induces glaucoma. J Clin Invest. 2017;127:3877–96.CrossRefPubMedPubMedCentral
13.
Kapiainen E, Elamaa H, Miinalainen I, Izzi V, Eklund L. Cooperation of angiopoietin-2 and angiopoietin-4 in Schlemm’s canal maintenance. Invest Ophthalmol Vis Sci. 2022;63:1.CrossRefPubMedPubMedCentral
14.
Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology. 2015;122:1802–10.CrossRefPubMed
15.
Matsumoto H, Hoshino J, Nakamura K, Nagashima T, Akiyama H. Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023;261:2945–52.CrossRefPubMed
16.
Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13:8747.CrossRefPubMedPubMedCentral
17.
Gabrielle P-H, Nguyen V, Wolff B, Essex R, Young S, Hunt A, et al. Intraocular pressure changes and vascular endothelial growth factor inhibitor use in various retinal diseases: long-term outcomes in routine clinical practice: data from the Fight Retinal Blindness! Registry. Ophthalmol Retina. 2020;4:861–70.CrossRefPubMed
18.
Novais EA, Baumal CR, Sarraf D, Freund KB, Duker JS. Multimodal imaging in retinal disease: A consensus definition. Ophthalmic Surg Lasers Imaging Retina. 2016;47:201–5.CrossRefPubMed
19.
Yannuzzi NA, Patel SN, Bhavsar KV, Sugiguchi F, Freund KB. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2014;158:319–e3272.CrossRefPubMed
20.
Ramsey DJ, McCullum JC, Steinberger EE, Zhang Y, Alwreikat AM, Cooper ML, et al. Intraocular pressure decreases in eyes with glaucoma-related diagnoses after conversion to aflibercept for treatment-resistant age-related macular degeneration. Eye (Lond). 2022;36:1813–9.CrossRefPubMed
21.
Rusu IM, Deobhakta A, Yoon D, Lee M, Slakter JS, Klancnik JM, et al. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments. Retina. 2014;34:2161–6.CrossRefPubMed
22.
Honjo J, Mukai R, Itagaki K, Tanaka K, Norikawa K, Kato Y, et al. Intraocular pressure changes during intravitreal aflibercept injection based on treat-and-extend regimen in Japanese patients with neovascular age-related macular degeneration and glaucoma. Jpn J Ophthalmol. 2024;68:91–5.CrossRefPubMed
23.
Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye (Lond). 2018;32:1010–20.CrossRefPubMed
24.
Van Bergen T, Jonckx B, Hollanders K, Sijnave D, Van de Velde S, Vandewalle E, et al. Inhibition of placental growth factor improves surgical outcome of glaucoma surgery. J Cell Mol Med. 2013;17:1632–43.CrossRefPubMedPubMedCentral
25.
Van Bergen T, Etienne I, Cunningham F, Moons L, Schlingemann RO, Feyen JHM, et al. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. Prog Retin Eye Res. 2019;69:116–36.CrossRefPubMed
26.
Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95.CrossRefPubMedPubMedCentral
27.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and Lucerne): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.CrossRefPubMed
28.
Khawaja AP, Cooke Bailey JN, Wareham NJ, Scott RA, Simcoe M, Igo RP, et al. Genome-wide analyses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma. Nat Genet. 2018;50:778–82.CrossRefPubMedPubMedCentral
29.
Thackaberry EA, Zhou Y, Zuch de Zafra CL, Fuh G, Lee CV, Sanowar S, et al. Rapid development of glaucoma via ITV nonselective ANGPT 1/2 antibody: A potential role for ANGPT/Tie2 signaling in primate aqueous humor outflow. Invest Ophthalmol Vis Sci. 2019;60:4097–108.CrossRefPubMed
Metadata
Title
Comparison of intraocular pressure changes in Japanese patients with neovascular age-related macular degeneration treated with aflibercept or faricimab
Authors
Junichiro Honjo
Ryo Mukai
Kanako Itagaki
Keiichiro Tanaka
Koki Norikawa
Yutaka Kato
Akihito Kasai
Yukinori Sugano
Tetsuju Sekiryu
Publication date
12-03-2025
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-024-01155-2